Key clinical point: Long noncoding ribonucleic acid (lncRNA) H19 and 10-11 translocation enzyme 1 (TET1) messenger RNA expression levels showed high diagnostic and predictive values for determining postoperative recurrence of uterine fibroids (UFs).

Major finding: lncRNA H19 (P = .010) and TET1 (P = .014) levels independently predicted UF recurrence. The area under the curve values of lncRNA H19 and TET1 for predicting UF recurrence were 0.814 (sensitivity, 81.13%; specificity, 77.27%) and 0.765 (sensitivity, 69.81%; specificity, 77.27%), respectively.

Study details: This study enrolled 75 patients with UFs who underwent surgical treatment and 60 healthy controls. Patients with UF were followed up for 2 years to evaluate postoperative recurrence of UFs.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Zhan X et al. Clinics. 2021 Sep 28. doi: 10.6061/clinics/2021/e2671.

Key clinical point: Long noncoding ribonucleic acid (lncRNA) H19 and 10-11 translocation enzyme 1 (TET1) messenger RNA expression levels showed high diagnostic and predictive values for determining postoperative recurrence of uterine fibroids (UFs).

Major finding: lncRNA H19 (P = .010) and TET1 (P = .014) levels independently predicted UF recurrence. The area under the curve values of lncRNA H19 and TET1 for predicting UF recurrence were 0.814 (sensitivity, 81.13%; specificity, 77.27%) and 0.765 (sensitivity, 69.81%; specificity, 77.27%), respectively.

Study details: This study enrolled 75 patients with UFs who underwent surgical treatment and 60 healthy controls. Patients with UF were followed up for 2 years to evaluate postoperative recurrence of UFs.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Zhan X et al. Clinics. 2021 Sep 28. doi: 10.6061/clinics/2021/e2671.

Key clinical point: Long noncoding ribonucleic acid (lncRNA) H19 and 10-11 translocation enzyme 1 (TET1) messenger RNA expression levels showed high diagnostic and predictive values for determining postoperative recurrence of uterine fibroids (UFs).

Major finding: lncRNA H19 (P = .010) and TET1 (P = .014) levels independently predicted UF recurrence. The area under the curve values of lncRNA H19 and TET1 for predicting UF recurrence were 0.814 (sensitivity, 81.13%; specificity, 77.27%) and 0.765 (sensitivity, 69.81%; specificity, 77.27%), respectively.

Study details: This study enrolled 75 patients with UFs who underwent surgical treatment and 60 healthy controls. Patients with UF were followed up for 2 years to evaluate postoperative recurrence of UFs.

Disclosures: No information on funding was available. The authors declared no conflict of interests.

Source: Zhan X et al. Clinics. 2021 Sep 28. doi: 10.6061/clinics/2021/e2671.

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.

Key clinical point: Signal intensity of the predominant uterine fibroid (UF) on T2-weighted images could predict volume reduction rate (VRR) after gonadotropin-releasing hormone (GnRH)-agonist treatment before uterine artery embolization.

Major finding: The ratio between the mean signal intensity of UF and mean signal intensity of the rectus abdominis (F/R) at an optimal cutoff value of 2.58 and 1.69 could predict VRR 50% or more and less than 30% with an area under the curve of 0.81 (95% confidence interval [CI], 0.62-0.96; sensitivity and specificity, 80%) and 0.84 (95% CI, 0.63-1.00; sensitivity, 100%; specificity, 70%), respectively.

Study details: This was a retrospective analysis of 30 women with a large UF who underwent magnetic resonance imaging (MRI) both before and after GnRH-agonist administration.

Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.

Source: Lee WJ et al. Acta Radiol. 2021 Sep 25. doi: 10.1177/02841851211038802.

Key clinical point: Nearly half the patients with uterine fibroids (UF) considered nonresponders to elagolix plus add-back therapy in the 2 phase 3 trials showed a clinically meaningful reduction in menstrual blood loss (MBL).

Major finding: Overall, 24% of patients treated with elagolix+add-back therapy were considered nonresponders as they did not meet 1 or more criteria among MBL less than 80 mL, 50% or more reduction in MBL, and/or premature treatment discontinuation. Of these, 19% met both the bleeding criterion but discontinued treatment and 26% met 1 bleeding criterion. At month 1, the least mean percent change in MBL in nonresponders who met both bleeding criteria was 80.3%.

Study details: Findings are from a pooled post hoc analysis of phase 3 Elaris UF-1 and UF-2 trials, including 549 premenopausal women with UF and heavy menstrual bleeding who received elagolix+add-back therapy or placebo.

Disclosures: This study was funded by AbbVie. Some investigators reported ties with various sources including Abbvie. Three authors declared being current/former employees and/or shareholders of AbbVie.

Source: Stewart EA et al. J Womens Health. 2021 Sep 28. doi: 10.1089/jwh.2021.0152.

Key clinical point: Nearly half the patients with uterine fibroids (UF) considered nonresponders to elagolix plus add-back therapy in the 2 phase 3 trials showed a clinically meaningful reduction in menstrual blood loss (MBL).

Major finding: Overall, 24% of patients treated with elagolix+add-back therapy were considered nonresponders as they did not meet 1 or more criteria among MBL less than 80 mL, 50% or more reduction in MBL, and/or premature treatment discontinuation. Of these, 19% met both the bleeding criterion but discontinued treatment and 26% met 1 bleeding criterion. At month 1, the least mean percent change in MBL in nonresponders who met both bleeding criteria was 80.3%.

Study details: Findings are from a pooled post hoc analysis of phase 3 Elaris UF-1 and UF-2 trials, including 549 premenopausal women with UF and heavy menstrual bleeding who received elagolix+add-back therapy or placebo.

Disclosures: This study was funded by AbbVie. Some investigators reported ties with various sources including Abbvie. Three authors declared being current/former employees and/or shareholders of AbbVie.

Source: Stewart EA et al. J Womens Health. 2021 Sep 28. doi: 10.1089/jwh.2021.0152.

Key clinical point: Nearly half the patients with uterine fibroids (UF) considered nonresponders to elagolix plus add-back therapy in the 2 phase 3 trials showed a clinically meaningful reduction in menstrual blood loss (MBL).

Major finding: Overall, 24% of patients treated with elagolix+add-back therapy were considered nonresponders as they did not meet 1 or more criteria among MBL less than 80 mL, 50% or more reduction in MBL, and/or premature treatment discontinuation. Of these, 19% met both the bleeding criterion but discontinued treatment and 26% met 1 bleeding criterion. At month 1, the least mean percent change in MBL in nonresponders who met both bleeding criteria was 80.3%.

Study details: Findings are from a pooled post hoc analysis of phase 3 Elaris UF-1 and UF-2 trials, including 549 premenopausal women with UF and heavy menstrual bleeding who received elagolix+add-back therapy or placebo.

Disclosures: This study was funded by AbbVie. Some investigators reported ties with various sources including Abbvie. Three authors declared being current/former employees and/or shareholders of AbbVie.

Source: Stewart EA et al. J Womens Health. 2021 Sep 28. doi: 10.1089/jwh.2021.0152.

Key clinical point: Preliminary data showed a low risk for uterine rupture with single-layer closure of the myometrium after laparoscopic myomectomy (LM) and therefore can be considered a safe option for subsequent pregnancies.

Major finding: Overall, 24 pregnant women underwent single-layer closure of the myometrium after LM. The mean duration between the operation and the first pregnancy was 10.2 months. Overall, 24 patients needed a cesarean section (C-section) delivery, 6 had a miscarriage, and 2 had an intrauterine pregnancy. Of these, 8 patients were pregnant again and underwent a C-section delivery. No cases of uterine rupture were observed.

Study details: Findings are from a retrospective study including 102 women who underwent single-layer sutured LM to remove uterine fibroids larger than 5 cm and associated with the myometrium.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Aksin S et al. Int J Clin Pract. 2021 Sep 15. doi: 10.1111/ijcp.14870.

Key clinical point: Preliminary data showed a low risk for uterine rupture with single-layer closure of the myometrium after laparoscopic myomectomy (LM) and therefore can be considered a safe option for subsequent pregnancies.

Major finding: Overall, 24 pregnant women underwent single-layer closure of the myometrium after LM. The mean duration between the operation and the first pregnancy was 10.2 months. Overall, 24 patients needed a cesarean section (C-section) delivery, 6 had a miscarriage, and 2 had an intrauterine pregnancy. Of these, 8 patients were pregnant again and underwent a C-section delivery. No cases of uterine rupture were observed.

Study details: Findings are from a retrospective study including 102 women who underwent single-layer sutured LM to remove uterine fibroids larger than 5 cm and associated with the myometrium.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Aksin S et al. Int J Clin Pract. 2021 Sep 15. doi: 10.1111/ijcp.14870.

Key clinical point: Preliminary data showed a low risk for uterine rupture with single-layer closure of the myometrium after laparoscopic myomectomy (LM) and therefore can be considered a safe option for subsequent pregnancies.

Major finding: Overall, 24 pregnant women underwent single-layer closure of the myometrium after LM. The mean duration between the operation and the first pregnancy was 10.2 months. Overall, 24 patients needed a cesarean section (C-section) delivery, 6 had a miscarriage, and 2 had an intrauterine pregnancy. Of these, 8 patients were pregnant again and underwent a C-section delivery. No cases of uterine rupture were observed.

Study details: Findings are from a retrospective study including 102 women who underwent single-layer sutured LM to remove uterine fibroids larger than 5 cm and associated with the myometrium.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Aksin S et al. Int J Clin Pract. 2021 Sep 15. doi: 10.1111/ijcp.14870.

Key clinical point: The uterine radial artery resistance index (RA-RI) was impaired after laparoscopic myomectomy (LM) and took almost 3 months to return to postoperative levels. However, restoration correlated negatively with the age of the patient.

Major finding: The median impedance of RA-RI was significantly higher 1 week after LM (0.87) vs before (0.73) and 3 months after (0.76) surgery (P < .001). There was a moderately significant correlation between the patient’s age and the rate of recovery at 3 months after LM (Pearson’s correlation coefficient, 0.54; P = .002).

Study details: Findings are from a retrospective study including 19 infertile women with uterine fibroid who underwent LM.

Disclosures: This work was funded by a grant from the Japanese Foundation for Research and Promotion of Endoscopy. The authors declared no conflict of interests.

Source: Ota K et al. J Obstet Gynaecol. 2021 Sep 23. doi: 10.1080/01443615.2021.1945011.

Key clinical point: The uterine radial artery resistance index (RA-RI) was impaired after laparoscopic myomectomy (LM) and took almost 3 months to return to postoperative levels. However, restoration correlated negatively with the age of the patient.

Major finding: The median impedance of RA-RI was significantly higher 1 week after LM (0.87) vs before (0.73) and 3 months after (0.76) surgery (P < .001). There was a moderately significant correlation between the patient’s age and the rate of recovery at 3 months after LM (Pearson’s correlation coefficient, 0.54; P = .002).

Study details: Findings are from a retrospective study including 19 infertile women with uterine fibroid who underwent LM.

Disclosures: This work was funded by a grant from the Japanese Foundation for Research and Promotion of Endoscopy. The authors declared no conflict of interests.

Source: Ota K et al. J Obstet Gynaecol. 2021 Sep 23. doi: 10.1080/01443615.2021.1945011.

Key clinical point: The uterine radial artery resistance index (RA-RI) was impaired after laparoscopic myomectomy (LM) and took almost 3 months to return to postoperative levels. However, restoration correlated negatively with the age of the patient.

Major finding: The median impedance of RA-RI was significantly higher 1 week after LM (0.87) vs before (0.73) and 3 months after (0.76) surgery (P < .001). There was a moderately significant correlation between the patient’s age and the rate of recovery at 3 months after LM (Pearson’s correlation coefficient, 0.54; P = .002).

Study details: Findings are from a retrospective study including 19 infertile women with uterine fibroid who underwent LM.

Disclosures: This work was funded by a grant from the Japanese Foundation for Research and Promotion of Endoscopy. The authors declared no conflict of interests.

Source: Ota K et al. J Obstet Gynaecol. 2021 Sep 23. doi: 10.1080/01443615.2021.1945011.

Key clinical point: Single-port laparoscopic myomectomy (LM) for treatment of uterine fibroids (UF) showed characteristics of lesser trauma, faster recovery, and higher patient satisfaction than the traditional 3-port LM.

Major finding: The specimen removal time, postoperative ambulation time, first exhaust time after surgery, and postoperative hospital stay were lower for single-port vs traditional 3-port LM (all P < .05). After 30 days of operation, the abdominal scar satisfaction score was higher in the single-port vs 3-port LM group (4.17 vs 3.47; P = .00). Intraoperative blood loss was similar in both groups (P > .05).

Study details: Findings are from a retrospective review of 120 patients with UFs who underwent LM. Overall, 60 patients underwent single-port LM, and the remaining 60 were treated with traditional 3-port LM.

Disclosures: This study was funded by the Liaoning Provincial Department of Science and Technology. The authors declared no conflict of interests.

Source: Jiang L et al. Front Oncol. 2021 Sep 24. doi: 10.3389/fonc.2021.722084.

Key clinical point: Single-port laparoscopic myomectomy (LM) for treatment of uterine fibroids (UF) showed characteristics of lesser trauma, faster recovery, and higher patient satisfaction than the traditional 3-port LM.

Major finding: The specimen removal time, postoperative ambulation time, first exhaust time after surgery, and postoperative hospital stay were lower for single-port vs traditional 3-port LM (all P < .05). After 30 days of operation, the abdominal scar satisfaction score was higher in the single-port vs 3-port LM group (4.17 vs 3.47; P = .00). Intraoperative blood loss was similar in both groups (P > .05).

Study details: Findings are from a retrospective review of 120 patients with UFs who underwent LM. Overall, 60 patients underwent single-port LM, and the remaining 60 were treated with traditional 3-port LM.

Disclosures: This study was funded by the Liaoning Provincial Department of Science and Technology. The authors declared no conflict of interests.

Source: Jiang L et al. Front Oncol. 2021 Sep 24. doi: 10.3389/fonc.2021.722084.

Key clinical point: Single-port laparoscopic myomectomy (LM) for treatment of uterine fibroids (UF) showed characteristics of lesser trauma, faster recovery, and higher patient satisfaction than the traditional 3-port LM.

Major finding: The specimen removal time, postoperative ambulation time, first exhaust time after surgery, and postoperative hospital stay were lower for single-port vs traditional 3-port LM (all P < .05). After 30 days of operation, the abdominal scar satisfaction score was higher in the single-port vs 3-port LM group (4.17 vs 3.47; P = .00). Intraoperative blood loss was similar in both groups (P > .05).

Study details: Findings are from a retrospective review of 120 patients with UFs who underwent LM. Overall, 60 patients underwent single-port LM, and the remaining 60 were treated with traditional 3-port LM.

Disclosures: This study was funded by the Liaoning Provincial Department of Science and Technology. The authors declared no conflict of interests.

Source: Jiang L et al. Front Oncol. 2021 Sep 24. doi: 10.3389/fonc.2021.722084.

Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.